Enanta Pharmaceuticals and Novartis have entered into an exclusive collaboration and license agreement for the worldwide development, manufacture and commercialization of Enanta’s lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. NS5A is a non-structural viral protein that’s essential to viral replication. Research has shown that targeting NS5A provides significant antiviral activity. Enanta received IND approval for the drug from the FDA. Enanta will...